Aclaris Therapeutics/$ACRS
1D1W1MYTD1Y5YMAX
Capital at risk
About Aclaris Therapeutics
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
- Ticker
- $ACRS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 71
- Headquarters
- Wayne, United States
- Website
- www.aclaristx.com
ACRS Metrics
BasicAdvanced
$646M
-
-$0.59
0.80
-
Price and volume
Market cap
$646M
Beta
0.8
52-week high
$6.60
52-week low
$1.74
Average daily volume
2.7M
Financial strength
Current ratio
3.462
Quick ratio
3.462
Long term debt to equity
0.01
Total debt to equity
0.015
Profitability
EBITDA (TTM)
-85.525
Gross margin (TTM)
-757.70%
Net profit margin (TTM)
-921.50%
Operating margin (TTM)
-1,040.43%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-28.98%
Return on equity (TTM)
-59.10%
Valuation
Price to revenue (TTM)
69.025
Price to book
4.93
Price to tangible book (TTM)
4.93
Price to free cash flow (TTM)
-9.124
Free cash flow yield (TTM)
-10.96%
Free cash flow per share (TTM)
-0.481
Growth
Revenue change (TTM)
-51.05%
Earnings per share change (TTM)
-55.19%
3-year revenue growth (CAGR)
-35.87%
3-year earnings per share growth (CAGR)
-27.76%
10-year earnings per share growth (CAGR)
-14.44%
What the Analysts think about ACRS
Analyst ratings (Buy, Hold, Sell) for Aclaris Therapeutics stock.
Analyst projections of the future price of Aclaris Therapeutics stock.
Bulls say / Bears say
ATI-052’s Phase 1a trial showed favourable safety, complete inhibition of its two target pathways and a roughly 45-day half-life, supporting the potential for convenient quarterly dosing. That profile could help it stand out if patient trials confirm efficacy. (GlobeNewswire)
ATI-2138’s Phase 2a atopic dermatitis study produced encouraging early signals, including a 77% improvement in EASI at week 12 for the lower dose and improvements in itch, body-surface area and quality of life. These results give Aclaris a clinical proof point beyond its antibody programmes. (GlobeNewswire)
Aclaris has several near-term catalysts, with placebo-controlled readouts planned for ATI-052 and bosakitug, while its cash and investments plus a subsequent $40.2 million equity raise are expected by management to fund operations through the end of 2028. That gives the company time to develop the pipeline without relying immediately on a partnership. (Aclaris Therapeutics)
The main value drivers are still unproven in patients: ATI-052 has only reported Phase 1a healthy-volunteer data, while its patient proof-of-concept readouts and bosakitug’s Phase 2 atopic dermatitis results were still pending for later in 2026. Negative or weak results could remove much of the pipeline’s current option value. (Aclaris Therapeutics, GlobeNewswire)
ATI-2138’s encouraging atopic dermatitis findings came from an open-label Phase 2a study, so they do not yet show performance against a placebo. The FDA’s Fast Track designation for lichen planus supports development speed but does not provide Phase 2b efficacy evidence. (GlobeNewswire, GlobeNewswire)
Aclaris is funding a rising loss-making operation with equity: it reported a $21.5 million second-quarter loss and a $41.3 million first-half loss, then sold 7.3 million shares for $40.2 million after quarter-end. Further development may therefore require more capital and dilute existing shareholders again. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
ACRS Financial Performance
Revenues and expenses
ACRS Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing ACRS
AllUSDGBPEUR
Fund name | Fund size | $ACRS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.